Efficacy and safety of entrectinib in children with extracranial solid or central nervous system (CNS) tumours harbouring NTRK or ROS1 fusions

Integrated data from three trials confirm entrectinib induces rapid and durable responses in children with NTRK or ROS1 fusion-positive tumours. The increased duration of safety monitoring does not demonstrate new or cumulative toxicity. Registered clinical trials: STARTRK-NG: NCT02650401; TAPISTRY: NCT04589845; STARTRK-2: NCT02568267.

Authors

Institutions

Publication Details

Journal
European Journal of Cancer
Published
2025-02-22
DOI
https://doi.org/10.1016/j.ejca.2025.115308
Citations
8
Primary Topic
Glioma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
13.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Efficacy and safety of entrectinib in children with extracranial solid or central nervous system (CNS) tumours harbouring NTRK or ROS1 fusions

Michela Casanova, Bo Ci, Jade Wulff, Ellen M. Basu et al.
8 citations
European Journal of Cancer
Glioma Diagnosis and Treatment
13.00
article

Efficacy and safety of entrectinib in children with extracranial solid or central nervous system (CNS) tumours harbouring NTRK or ROS1 fusions

Michela Casanova, Bo Ci, Jade Wulff, Ellen M. Basu, Quentin Campbell-Hewson, Amy E. Armstrong, Ami Vijay Desai, Amar Gajjar, Elizabeth Fox, Nicolás André, Giles W Robinson, Clare Devlin, Huanmin Wang, Alison K. Cardenas, Cornelis Martinus van Tilburg, Georgina Meneses‐Lorente, Katherine E. Hutchinson, Carolina Ryklansky, Yeming Wu, Aditi Bagchi
article en
8 citations

Abstract

Integrated data from three trials confirm entrectinib induces rapid and durable responses in children with NTRK or ROS1 fusion-positive tumours. The increased duration of safety monitoring does not demonstrate new or cumulative toxicity. Registered clinical trials: STARTRK-NG: NCT02650401; TAPISTRY: NCT04589845; STARTRK-2: NCT02568267.

European Journal of CancerVol. 220
St. Jude Children's Research Hospital (US), Memorial Sloan Kettering Cancer Center (US), Inserm (FR), German Cancer Research Center (DE), Washington University in St. Louis (US), Aix-Marseille Université (FR), Heidelberg University (DE), Royal Victoria Infirmary (GB), XinHua Hospital (CN), University Hospital Heidelberg (DE), Genesys (United States) (US), University of Chicago Medical Center (US), Align Technology (United States) (US), Gene Therapy Laboratory (FR), Roche (United Kingdom) (GB), Yahoo (United States) (US), Beijing Children’s Hospital (CN), Centre de Recherche en Cancérologie de Marseille (FR), Fondazione IRCCS Istituto Nazionale dei Tumori (IT), Hôpital de la Timone (FR)
Roche, F. Hoffmann-La Roche, St. Jude Children's Research Hospital, Children’s Oncology Group
Zero hunger
Openalex Percentile: Top 1%
Glioma Diagnosis and Treatment
13.00
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.